Oncotelic Therapeutics, Inc. – OTC:OTLC
Oncotelic Therapeutics stock price today
$0.051
+0.01
+40.11%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 6 hours
Oncotelic Therapeutics stock price monthly change
+23.61%
month
Oncotelic Therapeutics stock price quarterly change
+23.61%
quarter
Oncotelic Therapeutics key metrics
Market Cap | 23.68M |
Enterprise value | 26.07M |
P/E | 2.1 |
EV/Sales | N/A |
EV/EBITDA | 2.88 |
Price/Sales | N/A |
Price/Book | 0.67 |
PEG ratio | 0.02 |
EPS | -0.01 |
Revenue | N/A |
EBITDA | -467.97K |
Income | -7.78M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOncotelic Therapeutics stock price history
Oncotelic Therapeutics stock forecast
Oncotelic Therapeutics financial statements
| Jun 2023 | 0 | -6.75M | |
|---|---|---|---|
| Sep 2023 | 70K | 115.30K | 164.73% |
| Dec 2023 | 0 | -735.98K | |
| Mar 2024 | 0 | -408.67K |
| Jun 2023 | 30012093 | 18.08M | 60.26% |
|---|---|---|---|
| Sep 2023 | 30096053 | 18.01M | 59.84% |
| Dec 2023 | 30014952 | 18.40M | 61.31% |
| Mar 2024 | 29974410 | 18.72M | 62.47% |
| Jun 2023 | -448.56K | 0 | 440K |
|---|---|---|---|
| Sep 2023 | -248.85K | 0 | 335K |
| Dec 2023 | -372.61K | 0 | 275K |
| Mar 2024 | -231.41K | 0 | 250K |
Oncotelic Therapeutics alternative data
| Aug 2023 | 22 |
|---|---|
| Sep 2023 | 22 |
| Oct 2023 | 22 |
| Nov 2023 | 22 |
| Dec 2023 | 22 |
| Jan 2024 | 22 |
| Feb 2024 | 22 |
| Mar 2024 | 22 |
| Apr 2024 | 22 |
| May 2024 | 22 |
| Jun 2024 | 22 |
| Jul 2024 | 22 |
Oncotelic Therapeutics other data
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2024 | 500000 | 0 |
| Nov 2024 | 298499 | 0 |
-
What's the price of Oncotelic Therapeutics stock today?
One share of Oncotelic Therapeutics stock can currently be purchased for approximately $0.05.
-
When is Oncotelic Therapeutics's next earnings date?
Unfortunately, Oncotelic Therapeutics's (OTLC) next earnings date is currently unknown.
-
Does Oncotelic Therapeutics pay dividends?
No, Oncotelic Therapeutics does not pay dividends.
-
How much money does Oncotelic Therapeutics make?
Oncotelic Therapeutics has a market capitalization of 23.68M.
-
What is Oncotelic Therapeutics's stock symbol?
Oncotelic Therapeutics, Inc. is traded on the OTC under the ticker symbol "OTLC".
-
What is Oncotelic Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Oncotelic Therapeutics?
Shares of Oncotelic Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Oncotelic Therapeutics have?
As Jul 2024, Oncotelic Therapeutics employs 22 workers.
-
When Oncotelic Therapeutics went public?
Oncotelic Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 9 Aug 2021.
-
What is Oncotelic Therapeutics's official website?
The official website for Oncotelic Therapeutics is oncotelic.com.
-
Where are Oncotelic Therapeutics's headquarters?
Oncotelic Therapeutics is headquartered at 29397 Agoura Road, Agoura Hills, CA.
-
How can i contact Oncotelic Therapeutics?
Oncotelic Therapeutics's mailing address is 29397 Agoura Road, Agoura Hills, CA and company can be reached via phone at +65 06357000.
Oncotelic Therapeutics company profile:
Oncotelic Therapeutics, Inc.
oncotelic.comExchange:
OTC
Full time employees:
16
Industry:
Biotechnology
Sector:
Healthcare
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.
29397 Agoura Road
Agoura Hills, CA 91301
Agoura Hills, CA 91301
CIK: 0000908259
:
:
